Abstract

Keratin (KRT) 19 is a poor prognostic marker for hepatocellular carcinoma (HCC); however, regulatory mechanisms underlying its expression remain unclear. We have previously reported the presence of fibrous tumor stroma in KRT19-positive HCC, suggesting that cross-talk between cancer-associated fibroblasts (CAF) and tumor epithelial cells could regulate KRT19 expression. This was investigated in this study using an in vitro model of paracrine interaction between HCC cell lines (HepG2, SNU423) and hepatic stellate cells (HSC), a major source of hepatic myofibroblasts. HSCs upregulated transcription and translation of KRT19 in HCC cells via paracrine interactions. Mechanistically, hepatocyte growth factor (HGF) from HSCs activated c-MET and the MEK-ERK1/2 pathway, which upregulated KRT19 expression in HCC cells. Furthermore, AP1 (JUN/FOSL1) and SP1, downstream transcriptional activators of ERK1/2, activated KRT19 expression in HCC cells. In clinical specimens of human HCC (n = 339), HGF and KRT19 protein expression correlated with CAF levels. In addition, HGF or MET protein expression was associated with FOSL1 and KRT19 expression and was found to be a poor prognostic factor. Analysis of data from The Cancer Genome Atlas also revealed KRT19 expression was closely associated with CAF and MET-mediated signaling activities. These results provide insights into the molecular background of KRT19-positive HCC that display an aggressive phenotype.Significance: These findings reveal KRT19 expression in hepatocellular carcinoma is regulated by cross-talk between cancer-associated fibroblasts and HCC cells, illuminating new therapeutic targets for this aggressive disease. Cancer Res; 78(7); 1619-31. ©2018 AACR.

Highlights

  • Keratin 19 (KRT19) is a small type I cytokeratin, which lacks the tail domain common among cytokeratins [1]

  • KRT19 expression in hepatocellular carcinomas (HCC) is upregulated by paracrine factors from hepatic stellate cells

  • Our in vitro and human study demonstrated that KRT19 expression in HCCs was regulated by the cancer-associated fibroblasts (CAF)-derived hepatocyte growth factor (HGF) via the METERK1/2-activator protein 1 (AP1) and specificity protein 1 (SP1) axis, highlighting the molecular background of clinically aggressive KRT19-positive HCCs (Supplementary Fig. S8)

Read more

Summary

Introduction

Keratin 19 (KRT19) is a small (approximately 40 kDa) type I cytokeratin, which lacks the tail domain common among cytokeratins [1]. KRT19 is a marker for hepatic stem/progenitor cells [2, 3]. Mature hepatocytes express KRT8 and KRT18, while cholangiocytes express KRT7 and KRT19 [4]. Most hepatocellular carcinomas (HCC) do not express KRT19 like normal hepatocytes, 10%–28% of HCCs were reported to express KRT19, and were found to display a more invasive phenotype and poorer outcomes than those that do not, when treated using hepatic. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). Rhee: Department of Radiology, Yonsei University College of Medicine, Seoul, Korea

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call